Management of vasovagal syncope

Walter L. Atiga, Peter Rowe, Hugh Calkins

Research output: Contribution to journalArticle

Abstract

Vasovagal syncope is a common disorder of autonomic cardiovascular regulation that can be very disabling and result in a significant level of psychosocial and physical limitations. The optimal approach to treatment of patients with vasovagal syncope remains uncertain. Although many different types of treatment have been proposed and appear effective based largely on small nonrandomized studies and clinical series, there is a remarkable absence of data from large prospective clinical trials. However, based on currently available data, the pharmacologic agents most likely to be effective in the treatment of patients with vasovagal syncope include beta blockers, fludrocortisone, and alpha-adrenergic agonists. In this article, we provide a summary of the various therapeutic options that have been proposed for vasovagal syncope and review the clinical studies that form the basis of present therapy for this relatively common entity.

Original languageEnglish (US)
Pages (from-to)874-886
Number of pages13
JournalJournal of Cardiovascular Electrophysiology
Volume10
Issue number6
StatePublished - 1999

Fingerprint

Vasovagal Syncope
Fludrocortisone
Adrenergic alpha-Agonists
Therapeutics
Clinical Trials

Keywords

  • Neurally mediated syncope
  • Neurocardiogenic syncope
  • Vasodepressor
  • Vasovagal syncope

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology

Cite this

Management of vasovagal syncope. / Atiga, Walter L.; Rowe, Peter; Calkins, Hugh.

In: Journal of Cardiovascular Electrophysiology, Vol. 10, No. 6, 1999, p. 874-886.

Research output: Contribution to journalArticle

@article{d14e7787498f45abb8aa9b2ddd5dbae8,
title = "Management of vasovagal syncope",
abstract = "Vasovagal syncope is a common disorder of autonomic cardiovascular regulation that can be very disabling and result in a significant level of psychosocial and physical limitations. The optimal approach to treatment of patients with vasovagal syncope remains uncertain. Although many different types of treatment have been proposed and appear effective based largely on small nonrandomized studies and clinical series, there is a remarkable absence of data from large prospective clinical trials. However, based on currently available data, the pharmacologic agents most likely to be effective in the treatment of patients with vasovagal syncope include beta blockers, fludrocortisone, and alpha-adrenergic agonists. In this article, we provide a summary of the various therapeutic options that have been proposed for vasovagal syncope and review the clinical studies that form the basis of present therapy for this relatively common entity.",
keywords = "Neurally mediated syncope, Neurocardiogenic syncope, Vasodepressor, Vasovagal syncope",
author = "Atiga, {Walter L.} and Peter Rowe and Hugh Calkins",
year = "1999",
language = "English (US)",
volume = "10",
pages = "874--886",
journal = "Journal of Cardiovascular Electrophysiology",
issn = "1045-3873",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Management of vasovagal syncope

AU - Atiga, Walter L.

AU - Rowe, Peter

AU - Calkins, Hugh

PY - 1999

Y1 - 1999

N2 - Vasovagal syncope is a common disorder of autonomic cardiovascular regulation that can be very disabling and result in a significant level of psychosocial and physical limitations. The optimal approach to treatment of patients with vasovagal syncope remains uncertain. Although many different types of treatment have been proposed and appear effective based largely on small nonrandomized studies and clinical series, there is a remarkable absence of data from large prospective clinical trials. However, based on currently available data, the pharmacologic agents most likely to be effective in the treatment of patients with vasovagal syncope include beta blockers, fludrocortisone, and alpha-adrenergic agonists. In this article, we provide a summary of the various therapeutic options that have been proposed for vasovagal syncope and review the clinical studies that form the basis of present therapy for this relatively common entity.

AB - Vasovagal syncope is a common disorder of autonomic cardiovascular regulation that can be very disabling and result in a significant level of psychosocial and physical limitations. The optimal approach to treatment of patients with vasovagal syncope remains uncertain. Although many different types of treatment have been proposed and appear effective based largely on small nonrandomized studies and clinical series, there is a remarkable absence of data from large prospective clinical trials. However, based on currently available data, the pharmacologic agents most likely to be effective in the treatment of patients with vasovagal syncope include beta blockers, fludrocortisone, and alpha-adrenergic agonists. In this article, we provide a summary of the various therapeutic options that have been proposed for vasovagal syncope and review the clinical studies that form the basis of present therapy for this relatively common entity.

KW - Neurally mediated syncope

KW - Neurocardiogenic syncope

KW - Vasodepressor

KW - Vasovagal syncope

UR - http://www.scopus.com/inward/record.url?scp=0033030337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033030337&partnerID=8YFLogxK

M3 - Article

C2 - 10376927

AN - SCOPUS:0033030337

VL - 10

SP - 874

EP - 886

JO - Journal of Cardiovascular Electrophysiology

JF - Journal of Cardiovascular Electrophysiology

SN - 1045-3873

IS - 6

ER -